优化的BCMA/CS1双特异性TRuC-T细胞分泌IL-7和CCL21,可有效控制多发性骨髓瘤
Min Li1, Rong Zheng1,2, Zairu Liu1,3
1Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China.
优化的T细胞受体融合构造 (TRuC) - - 分泌IL-7和CCL21的T细胞显示出对多发性骨髓瘤的增强疗效. 这些新型BC-7×21 TRuC-T细胞在体内表现出改善的持续性和瘤抑制.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞疗法细胞疗法
背景情况:
- 卡尔-T细胞疗法对多发性骨髓瘤有希望,但面临着抗原逃逸等挑战.
- T细胞受体融合构造 (TRuC) -T细胞提供了一个潜在的替代方案,通过独立于MHC的瘤向.
- 众所周知,介质素-7 (IL-7) 和C-C动机化学因子联结体21 (CCL21) 能够增强T细胞功能.
研究的目的:
- 为多发性骨髓瘤治疗设计和评估针对BCMA和CS1的两种特异性TRuC-T细胞.
- 研究IL-7和CCL21联合表达对TRuC-T细胞功能和疗效的影响.
- 优化TRuC-T细胞结构以改善抗髓瘤活性.
主要方法:
- 通过配对TCR/CD3子单元,构建了针对BCMA和CS1的两种特异性TRuC-T细胞.
- 生成的BCMA/CS1双特异性TRuC-T细胞被设计为分泌IL-7和CCL21 (BC-7×21 TRuC-T细胞).
- 在多发性骨髓瘤的体外和体外模型中,特征和测试了TRuC-T细胞变异.
主要成果:
- 优化的TRuC-T细胞结构 (B-3G-C-3E) 显示出优异的髓瘤特异性细胞毒性.
- 在体外,BC-7×21 TRuC-T细胞表现出增强的增殖,化学毒性和细胞毒性.
- 在多发性骨髓瘤异体移植模型中,BC-7×21 TRuC-T细胞在体内持续性得到改善,并显著抑制瘤.
结论:
- 改造的BC-7×21 TRuC-T细胞代表了一个有前途的新疗法策略.
- 优化TCR/CD3子单元和细胞因子联合表达,可增强多发性髓瘤的TRuC-T细胞疗法.
- 这种方法可以为复发性/耐药性多发性骨髓瘤提供有效的治疗方法.
更多相关视频
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
